Access TOC
Request Sample
December 2024
The global cell therapy raw materials market size is calculated at US$ 5.43 in 2024, grew to US$ 6.75 billion in 2025, and is projected to reach around US$ 48.54 billion by 2034. The market is expanding at a CAGR of 24.5% between 2025 and 2034. The cell therapy raw materials market is growing significantly due to growing demand of cell therapies invarious diseases such as cancer, various rare disease, and genetic disorders.
Unlock Infinite Advantages: Subscribe to Annual Membership
Substances utilized in the production of tissue-engineered products, gene therapy, or cell therapy that are not meant to be included in the finished product are known as raw materials. Cell isolation reagents, culture, cryopreservation medium, and disposables like plasticware and bioprocessing bags are examples of raw materials. The choice of raw materials used in the production of cell therapies can significantly affect the product's safety and effectiveness. The manufacturing components of a cell treatment are essential to creating a safe and repeatable product. A cell therapy's development time may be shortened, prices can be significantly decreased, and the chances of regulatory clearance can be increased by properly acquiring materials early on from reputable vendors that produce goods, especially for cell therapies.
As seen by the increasing number of clinical studies and regulatory-approved treatments, the area of cell and gene therapy is developing quickly. The examination of the materials and manufacturing methods utilized to create the desired cell or gene therapy product is evolving along with the variety of cell types, technological platforms, and target illnesses.
By forecasting the function and potency of cell products, artificial intelligence (AI) enhances their characterization and optimization in cell therapy. AI also improves sophisticated microscopy methods, making it possible to do precise, non-invasive, quantitative studies of living cell cultures. By accelerating development, anticipating interactions with tissues, and improving biomaterial and scaffold designs, artificial intelligence (AI) improves tissue engineering. This reduces trial and error, which results in quicker and more economical inventions. AI and regenerative medicine together have enormous revolutionary potential, offering novel therapeutic approaches and successful therapies.
High Demand in Cancer Treatment
The cell therapy raw material market is seen significant growth in recent years and is expected to grow significantly due to the growing use of cell therapy in cancer treatment. One of the most promising methods for treating cancer is cancer cell therapy. T cells that have been genetically modified are potent new medications that give cancer patients hope for a cure. Cell therapies are presently being tested in clinical trials for a number of cancer types, both on their own and in conjunction with other treatments.
For instance,
Strict Regulatory Requirements & Quality Check
Manufacturers of cell therapy must guarantee the quality of their raw materials, whether they are created internally or obtained from a third party. The FDA places a strong emphasis on using "the highest quality" materials available. Several contamination control and detection techniques are used to assess raw material safety in order to minimize any residues that might endanger the final product or cause harm. Many procedures are followed to maintain the high quality of the raw materials, which increases time, energy, resources, and efforts, ultimately leading to the high cost of the final raw materials.
Usage of Regenerative Medicine
Enhancing the body's healing system is the ultimate objective of stem cell-based treatment, a significant area of regenerative medicine. A promising future where damaged body components may be replaced, revived, and healed is promised by regenerative medicine. Regenerative medicine has applications in almost every area of molecular engineering and the medical sciences. Furthermore, a number of illnesses have been successfully modeled using stem cells. For medication development and research, these illness models offer a great platform for testing.
By product, the media segment held the major share of the cell therapy raw materials market in 2024. Cell culture mediums are in more demand than ever before due to the growing production of biotherapeutics for the treatment of non-communicable illnesses, including rheumatoid arthritis, diabetes, cancer, and others. The outcome of cell culture experiments is greatly impacted by the selection of cell culture medium, which is a crucial decision. The foundation for producing the cells required for cell therapy is the cell culture medium. As a result, it is the most sought-after raw material on the market. The kind and amount of media vary according to the production and cell type. While many pharmaceutical and biopharmaceutical businesses contract with third-party companies for significant volumes of media, many other companies create media internally. Popular cell culture medium formulations are currently offered for sale.
By product, the antibodies segment is estimated to grow at the fastest rate in the cell therapy raw materials market during the forecast period. Every stage of the cellular immunotherapy process depends on antibodies. Both the cellular input and the finished immune cell therapy product may be isolated, activated, and characterized using them. The biological sciences rely heavily on antibodies, and the subject of antibody engineering is one that is always expanding. They are essential research reagents due to their excellent specificity and selectivity for distinct protein targets. More significantly, antibodies are a raw material for medicines that can save lives. In order to guarantee functional antibody distribution in any situation, quality is another reason why it cannot be compromised and should be the primary focus of the development and production process.
By end-use, the biopharmaceutical & pharmaceutical companies segment held the largest share of the cell therapy raw materials market in 2024. Pharmaceutical companies are using cell therapy to address complex medical conditions and increase the number of available treatment options. To increase their patent portfolios, pharmaceutical companies are focusing on innovation and making strategic investments in gene and cell therapies. Putting oneself at the forefront of industry advances and forming lucrative alliances with partners are the objectives of these investments. The importance of gene and cell therapy to the pharmaceutical industry is demonstrated by some of the most recent partnerships.
By end-use, the CMOs & CROs segment is anticipated to grow at the fastest CAGR in the cell therapy raw materials market during 2025-2034. In an effort to overcome industry obstacles and address resource shortages, biotechnology, and pharmaceutical companies often go to outside vendors for research and manufacturing assistance, most commonly to CROs, CMOs, or CDMOs. Both CDMOs and bio/pharma companies are still investing in the development and production of cell and gene therapies, which constitute a specialized but growing market on a product basis. Since the industry's capacity for these new modalities is limited, CDMOs of all sizes are investing in both manufacturing capacity and research & development.
North America dominated the cell therapy raw materials market share by 47% in 2023. Supportive government regulations, a growing demand for novel therapies, and concerted efforts by major industry players to enhance cell therapy products that cure a variety of chronic ailments may all be responsible for the region's supremacy. Additionally, a lot of well-known companies that manufacture and market cell-based products are situated in North America, which is increasing demand for human raw materials for cell therapy and growing the market. Furthermore, competition is heightened as businesses strive to solidify their positions in the rapidly evolving cell therapy market through joint ventures between larger industry players and smaller biotechnology companies.
For instance,
Asia Pacific is estimated to host the fastest-growing cell therapy raw materials market during the forecast period. This increase is due to the increased demand for sophisticated cell therapies and the increased focus on biotechnology. Major industry players' increasing R&D efforts, strategic alliances, and the construction of manufacturing facilities are all contributing factors to the market's growth. Furthermore, China's cell therapy raw materials market held the largest market share in the Asia-Pacific area, while India's market for cell therapy human raw materials expanded at the fastest pace.
For instance,
In September 2024, Dana Cipriano, Vice President of Analytical Services for SK Pharmteco, mentioned that the supply chain's safety and integrity are crucial for goods in the rapidly expanding cell and gene therapy industries. Our collaboration with Cryoport is a testament to our dedication to our clients, as we strive to deliver the best services possible, particularly designed to satisfy their requirements and those of the patients they care for.
By Product
By End-use
By Region
December 2024
December 2024
December 2024
December 2024
Annual Access, Limitless Research! Unlock all market research reports with our annual subscription. Stay on top of market trends and crucial insights year-round!
2500+
Client Queries in 20235000+
Insights Published60+
Consulting Projects Per Year40+
Analysts